Elixinol Wellness completes US asset sale for $465,000

• Elixinol Wellness completed the divestment of its United States business to Ananda Health.
• The transaction generated $465,000 in overall proceeds, releasing $250,000 in upfront funds.
• The exit aims to streamline operations and reduce regulatory risk while refocusing on Australia.

Elixinol Wellness (ASX:EXL) completed the sale of its American operations to Ananda Health on Sept. 4 for a total headline consideration of approximately $465,000.

The divestment directly follows the original transaction agreement reached between the two parties on Aug. 31 after satisfying key closing conditions.

The deal delivers $250,000 in upfront cash released from escrow on Sept. 7, alongside remaining deferred and contingent proceeds capped at $215,000.

To ensure an orderly business transition, the company agreed to provide customer service, operational, and marketing support for up to six weeks.

The company stated that the divestment simplifies operations while reducing exposure to the evolving regulatory landscape in the United States.

Following the announcement, the Elixinol Wellness share price was unchanged at $0.0080.